Loading clinical trials...
Loading clinical trials...
Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep
Conditions
Interventions
NBI-827104
Placebo
Locations
15
United States
Neurocrine Clinical Site
Orange, California, United States
Neurocrine Clinical Site
Aurora, Colorado, United States
Neurocrine Clinical Site
Washington D.C., District of Columbia, United States
Neurocrine Clinical Site
Miami, Florida, United States
Neurocrine Clinical Site
Rochester, Minnesota, United States
Neurocrine Clinical Site
Durham, North Carolina, United States
Start Date
April 26, 2021
Primary Completion Date
August 8, 2022
Completion Date
October 11, 2022
Last Updated
September 5, 2025
NCT07227857
NCT07010471
NCT06938542
NCT05226780
NCT07396883
NCT03936777
Lead Sponsor
Neurocrine Biosciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions